自从去年礼来在阿尔兹海默症药物临床三期失败后，制药界同仁们都表达了敬意，鼓励其继续开发新型药物，这不今年年初花了9.6亿美元收了CoLucid制药从而获得了自己曾经放弃开发的三期偏头痛药物。礼来，新药开发从未止步。。。
礼来2016年研发支出在制药企业排名第八位
这不2017年6月8日，礼来官网宣布与 KeyBioscience AG 达成新的合作协议开发新型双糊精及降钙素受体激动剂Dual Amylin Calcitonin Receptor Agonists (DACRAs)治疗代谢性疾病，比如2型糖尿病，该类药物可以提高胰岛素敏感性并促进糖尿病患者的体重减轻。合作包括使用后者DACRA平台包括多个化合物 KBP-042, KBP-089和KBP-056。其中KBP-042已经启动2期临床试验，其他合作项目已经处于临床前和I期临床试验以测试活性。这一合作将帮助礼来在糖尿病领域进一步增强其竞争力。
KeyBioscience是北欧生物科学的子公司。就在几个月前，该公司报告称，它已经与Enteris BioPharma达成一项协议，使用Enteris BioPharma的技术来开发其代谢肽的口服制剂。
交易细节：礼来获得这些新型分子的全球研发和商业化权益，作为回报，同时首付5500万美元，KeyBioscience可以获得未来潜在研发、注册和商业化里程碑付款，以及未来产品销售分成。
KeyBioscience的董事会主席Morten对于合作的评论：
"We are extremely excited about the promise of this new mechanism, which could potentially improve insulin sensitivity, reduce weight and improve blood glucose control," said Morten Karsdal, chairman of the board, KeyBioscience AG. "The dual activation of the calcitonin and amylin receptors is exciting research in the diabetes space. We look forward to partnering with Lilly to advance this important work."
The dual activation of calcitonin and amylin receptors is thought to improve insulin sensitivity, suppress food intake, reduce fat deposition, improve blood glucose levels and cause weight reduction.
全球糖尿病现状
More than 400 million people around the world have diabetes, according to the International Diabetes Federation, and approximately 9 of 10 people with diabetes have type 2 diabetes. In addition to diet and exercise, current therapies for type 2 diabetes include insulins, oral treatments, and non-insulin injectables.
礼来糖尿病总裁Enrique Conterno评论：
"This is an exciting opportunity," said Enrique Conterno, president, Lilly Diabetes and Lilly USA. "Our strategic collaboration with KeyBioscience AG will open the door to a potentially innovative treatment approach for people with type 2 diabetes and, possibly, other metabolic conditions."
About KeyBioscience and Nordic Bioscience
KeyBioscience is a fully owned subsidiary of Nordic Bioscience, a Danish Biotech company headquartered in Copenhagen, Denmark. Nordic Bioscience is engaged in clinical research and precision medicine using unique biomarker technologies. Combining experience in preclinical and clinical research enables Nordic Bioscience to help provide a faster and smarter detection of signals of the potential clinical viability of drug candidates. Having worked for more than 25 years in biomarker development and clinical trials, Nordic Bioscience has acquired extensive expertise in rheumatology and fibrosis in particular.
For more information about Nordic Bioscience, visit us at http://www.nordicbioscience.com/
欢迎关注药物简讯公众号，扫描下方二维码！最新国内外医药行业热点一起共同探讨学习！
